CEBPA and neoplasm: Treatment with therapeutic saRNA overexpressing C/EBPα (MTL-C/EBPα) in hepatic cancer patients indicated that the number of monocytic myeloid-derived suppressor cells (M-MDSCs) and M2 tumor-associated MΦs (TAMs) were significantly reduced [29], suggesting that C/EBPα attenuates the negative immunoregulatory function of MΦs after MΦ reprogramming.